Loading...
XNAS
SENS
Market cap2.59bUSD
Jul 09, Last price  
5.35USD
1D
0.75%
1Q
-19.91%
Jan 2017
100.37%
IPO
55.07%
Name

Senseonics Holdings Inc

Chart & Performance

D1W1MN
XNAS:SENS chart
P/E
—
P/S
72.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.64%
Rev. gr., 5y
48.10%
Revenues
35m
+56.89%
17,000038,000332,0006,373,00018,913,00021,301,0004,949,00013,675,00016,389,00022,390,00022,472,00035,257,000
Net income
-69m
L-12.09%
-18,779,000-18,885,000-29,877,000-43,930,000-59,101,000-93,971,000-115,549,000-175,168,000-302,474,000142,119,000-60,392,000-78,616,000-69,113,000
CFO
-59m
L-2.21%
-17,167,000-19,270,000-25,465,000-38,016,000-55,739,000-90,771,000-136,047,000-67,422,000-56,078,000-66,312,000-70,163,000-60,465,000-59,129,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
URL
https://www.senseonics.com/
IPO date
Mar 04, 2015
Employees
121
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT